Syndax Pharmaceuticals (NASDAQ:SNDX) issued its earnings results on Thursday. The company reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.07, Fidelity Earnings reports. Syndax Pharmaceuticals had a negative return on equity of 108.44% and a negative net margin of 4,310.68%. The company had revenue of $0.38 million for the quarter, compared to analyst estimates of $0.38 million.
NASDAQ SNDX traded up $0.01 on Friday, reaching $6.97. The company had a trading volume of 186,700 shares, compared to its average volume of 163,226. The stock has a market capitalization of $194.57 million, a P/E ratio of -2.39 and a beta of 2.39. The company’s fifty day moving average is $7.05 and its 200 day moving average is $8.12. Syndax Pharmaceuticals has a 52-week low of $3.39 and a 52-week high of $11.11. The company has a quick ratio of 4.90, a current ratio of 4.90 and a debt-to-equity ratio of 0.01.
A number of brokerages have recently weighed in on SNDX. Zacks Investment Research lowered Syndax Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, October 12th. HC Wainwright reaffirmed a “buy” rating on shares of Syndax Pharmaceuticals in a research report on Tuesday, July 16th. ValuEngine lowered Syndax Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Tuesday, October 29th. Cowen reaffirmed a “buy” rating on shares of Syndax Pharmaceuticals in a research report on Friday. Finally, Nomura reaffirmed a “buy” rating and set a $16.00 target price on shares of Syndax Pharmaceuticals in a research report on Sunday, August 11th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company. Syndax Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $12.96.
Syndax Pharmaceuticals Company Profile
Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company's lead product candidates include entinostat, which is in Phase III clinical trials for the treatment of advanced hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) breast cancer; and SNDX-5613 inhibitor that targets the binding interaction of Menin with mixed lineage leukemia-rearranged and acute myeloid leukemia with a mutated nucleophosmin 1.
See Also: P/E Growth (PEG)
Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.